BioCryst Pharmaceuticals 8-K Report: Key Financial Insights & Recent Developments

Based on the provided financial report section, here are the key insights extracted:

Company Information:

Name: BioCryst Pharmaceuticals, Inc.
CIK (Central Index Key): 0000882796
Ticker Symbol: BCRX
Exchange: NASDAQ
Address: 4505 Emperor Blvd. Suite 200, Durham, NC 27703
Contact Number: (919) 859-1302

Filing Information:

Filing Type: 8-K
Filing Date: January 8, 2025

Financial Metrics:

Reporting Period: The report is as of January 8, 2025, which suggests it may contain current or recent significant events affecting the company.
Currency: The financial data is reported in USD (United States Dollar).
Shares: The report includes details related to shares, indicating possible stock-related disclosures or events.

Regulatory References:

The document adheres to XBRL (eXtensible Business Reporting Language) standards, which is used for reporting financial data to regulatory bodies like the SEC.

Tax Identification:

EIN (Employer Identification Number): 62-1413174, which is important for tax identification purposes.

Insights:

The filing date being recent (January 2025) indicates that the information may pertain to significant events or updates that investors should be aware of.
The use of an 8-K filing suggests that the company may have had an important event or change in financial condition, operations, or management that needs to be disclosed to the SEC and investors.
Investors should look for the specific details in the full 8-K report to understand the nature of the event and its potential impact on the stock price and company operations.

Overall, this section gives a snapshot of BioCryst Pharmaceuticals' essential corporate and regulatory information that may be relevant for stakeholders and investors monitoring the company's activities.